Kajiwara T
Nihon Seikeigeka Gakkai Zasshi. 1979 Nov;53(11):1595-605.
Although D-Penicillamine (D-PeA) administration is getting popular in the treatment of rheumatoid arthritis (RA), the mechanism by which D-PeA produced therapeutic effect has not been fully elucidated. D-PeA had been shown to exert an antivitamine B6 effect. However, it has not been precisely confirmed if clinical dose of D-PeA induces vitamine B6 (VB6) deficiency. In order to clarify these questions, biochemical analyses of bone and skin collagens and determination of VB6 content in soft tissues have been performed in the rats administrated therapeutic dose of D-PeA. VB6 deficiency was not observed in the brain and skin from rats fed on normal diet containing D-PeA (13.0--33.5 mg/kg wt). There were no significant changes in the stability of collagen from bone and skin. On the other hand, significant VB6 deficiency and reduced stability of collagen were observed in rats fed on VB6 deficient diet containing the same amount of D-PeA. Aldehyde formation of collagen molecule and cross-link formation of collagen were also found to be suppressed. The same results were obtained from analyses in rats fed on VB6 deficient diet without D-PeA administration. These data indicate that D-PeA is not capable of producing VB6 deficiency in the dosage employed in patients. However, in the treatment for patients who are not taking enough nutrition, the possibility of VB6 deficiency can not be neglected. Once VB6 deficiency is induced by D-PeA administration, severe connective tissue disorder may be produced, since VB6 is required for enzymic activity of lysyl oxidase. It is unlikely that the therapeutic effects of D-PeA in the treatment of RA are produced the the disturbance of collagen cross-link formation as discussed before. Immunologic reactions of D-PeA may play more important role in the improvement of clinical symptoms of this disease.
尽管D-青霉胺(D-PeA)在类风湿性关节炎(RA)治疗中的应用日益广泛,但其产生治疗效果的机制尚未完全阐明。D-PeA已被证明具有抗维生素B6的作用。然而,尚未确切证实临床剂量的D-PeA是否会导致维生素B6(VB6)缺乏。为了阐明这些问题,对给予治疗剂量D-PeA的大鼠进行了骨和皮肤胶原蛋白的生化分析以及软组织中VB6含量的测定。在喂食含D-PeA(13.0 - 33.5 mg/kg体重)的正常饮食的大鼠的脑和皮肤中未观察到VB6缺乏。骨和皮肤胶原蛋白的稳定性没有显著变化。另一方面,在喂食含相同量D-PeA的VB6缺乏饮食的大鼠中观察到显著的VB6缺乏和胶原蛋白稳定性降低。还发现胶原蛋白分子的醛形成和胶原蛋白的交联形成受到抑制。在未给予D-PeA的VB6缺乏饮食喂养的大鼠的分析中也获得了相同的结果。这些数据表明,D-PeA在所用于患者的剂量下不会导致VB6缺乏。然而,在治疗营养摄入不足的患者时,VB6缺乏的可能性不可忽视。一旦因给予D-PeA而诱发VB6缺乏,可能会产生严重的结缔组织紊乱,因为赖氨酰氧化酶的酶活性需要VB6。D-PeA在RA治疗中的治疗效果不太可能如前所述是由胶原蛋白交联形成的紊乱所产生的。D-PeA的免疫反应可能在改善该疾病的临床症状中起更重要的作用。